Calliditas Therapeutics
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1991-01-01
- Employees
- 195
- Market Cap
- -
- Website
- http://www.pharmalink.se
- Introduction
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-04-03
- Lead Sponsor
- Calliditas Therapeutics AB
- Target Recruit Count
- 124
- Registration Number
- NCT00160082
- Locations
- 🇸🇪
Huddinge University Hospital, Stockholm, Sweden
🇸🇪Uppsala Academic Hospital, Uppsala, Sweden
🇸🇪Sahlgrenska University Hospital, Gothenburg, Sweden
© Copyright 2024. All Rights Reserved by MedPath